Characterizing ligands for farnesoid X receptor-available in vitro test systems for farnesoid X receptor modulator development

Expert Opinion on Drug Discovery

Volumn 9, Issue 1, 2014, Pages 27-37

  Merk, Daniel ^a   Steinhilber, Dieter ^a   Schubert Zsilavecz, Manfred ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Assay; Chenodeoxycholic acid (CDCA); Coactivator recruitment assay; Farnesoid X receptor; GW4064; Nuclear receptors; Reporter gene assay

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; BETA GALACTOSIDASE; CHOLESTEROL 7ALPHA MONOOXYGENASE; FARNESOID X RECEPTOR; FIREFLY LUCIFERASE; HEAT SHOCK PROTEIN 27; LIGAND; YELLOW FLUORESCENT PROTEIN;

BINDING ASSAY; CELL ASSAY; DRUG DEVELOPMENT; DRUG POTENCY; DRUG TARGETING; FLUORESCENCE POLARIZATION IMMUNOASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE ACTIVATION; IN VITRO STUDY; LIGAND BINDING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR BINDING ASSAY; REPORTER GENE; REVIEW; SCINTILLATION PROXIMITY ASSAY; SURFACE PLASMON RESONANCE;

ANIMALS; HUMANS; LIGANDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION, GENETIC;

EID: 84890490845     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.860129     Document Type: Review

References (63)

1. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: Natural ligands for an orphan nuclear receptor. Science 1999;284(5418):1365-8
2. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999;284(5418):1362-5
3. Wang H, Chen J, Hollister K, et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999;3(5):543-53
4. Wang Y, Chen W, Moore DD, Huang W. FXR: A metabolic regulator and cell protector. Cell Res 2008;18(11):1087-95
5. Fiorucci S, Mencarelli A, Distrutti E, et al. Targetting farnesoid-X-receptor: From medicinal chemistry to disease treatment. Curr Med Chem 2010;17(2):139-59. Reviews physiological and pathophysiological roles of FXR.
6. Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2010;51(4):771-84
7. Dufer M, Horth K, Wagner R, et al. Bile acids acutely stimulate insulin secretion of mouse b-cells via farnesoid X receptor activation and K(ATP) channel inhibition. Diabetes 2012;61(6):1479-89. Describes a potential role of FXR in diabetes and insulin resistance.
8. Dufer M, Horth K, Krippeit-Drews P, Drews G. The significance of the nuclear farnesoid X receptor (FXR) in b cell function. Islets 2012;4(5):333-8
9. Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006;103(4):1006-11
10. Zhang Y, Yin L, Anderson J, et al. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. J Biol Chem 2010;285(5):3035-43
11. Renga B, Mencarelli A, Cipriani S, et al. The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation. PLoS One 2013;8(1):e54472
12. Nijmeijer RM, Gadaleta RM, van Mil SWC, et al. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. PLoS One 2011;6(8):e23745
13. Wildenberg ME, van den Brink GR. FXR activation inhibits inflammation and preserves the intestinal barrier in IBD. Gut 2011;60(4):432-3
14. Wang X, Fu X, van Ness C, et al. Bile acid receptors and liver cancer. Curr Pathobiol Rep 2013;1(1):29-35
15. Vaquero J, Briz O, Herraez E, et al. Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds. Biochim Biophys Acta 2013;1833(10):2212-19
16. Merk D, Steinhilber D, Schubert-Zsilavecz M. Medicinal chemistry of farnesoid X receptor ligands: From agonists and antagonists to modulators. Future Med Chem 2012;4(8):1015-36
17. Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl- chenodeoxycholic acid (6-ECDCA): A potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002;45(17):3569-72. Discovery and in vitro characterization of 6-ECDCA-the farthest developed FXR ligand in clinical trials.
18. Maloney PR, Parks DJ, Haffner CD, et al. Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 2000;43(16):2971-4. Discovery and in vitro characterization of GW4064.
19. Downes M, Verdecia MA, Roecker AJ, et al. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell 2003;11(4):1079-92
20. Tsai C, Liang J, Lin H. Sesquiterpenoids from Atractylodes macrocephala act as farnesoid X receptor and progesterone receptor modulators. Bioorgan Med Chem Lett 2012;22(6):2326-9
21. Lundquist JT, Harnish DC, Kim CY, et al. Improvement of physiochemical properties of the tetrahydroazepinoindole series of Farnesoid X Receptor (FXR) agonists: Beneficial modulation of lipids in primates. J Med Chem 2010;53(4):1774-87
22. Mehlmann JF, Crawley ML, Lundquist JT, et al. Pyrrole[2,3-d] azepino compounds as agonists of the farnesoid X receptor (FXR). Bioorgan Med Chem Lett 2009;19(18):5289-92. Describes a reporter gene assay for FXR in stably transfected cells.
23. Ginzinger DG. Gene quantification using real-time quantitative PCR: An emerging technology hits the mainstream. Exp Hematol 2002;30(6):503-12
24. Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): Trends and problems. J Mol Endocrinol 2002;29(1):23-39
25. Putra MY, Bavestrello G, Cerrano C, et al. Polyhydroxylated sterols from the Indonesian soft coral Sinularia sp. and their effect on farnesoid X-activated receptor. Steroids 2012;77(5):433-40
26. Renga B, Mencarelli A, D'Amore C, et al. Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PLoS One 2012;7(1):e30443
27. Schuster D, Markt P, Grienke U, et al. Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation. Bioorgan Med Chem 2011;19(23):7168-80
28. Marinozzi M, Carotti A, Sansone E, et al. Pyrazole[3,4-e][1,4]thiazepin- 7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists. Bioorgan Med Chem 2012;20(11):3429-45
29. Sepe V, Bifulco G, Renga B, et al. Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of Farnesoid-X-Receptor. J Med Chem 2011;54(5):1314-20
30. Gioiello A, Macchiarulo A, Carotti A, et al. Extending SAR of bile acids as FXR ligands: Discovery of 23-N-(carbocinnamyloxy)-3a,7a-dihydroxy-6a-ethyl- 24-nor-5b-cholan-23-amine. Bioorgan Med Chem 2011;19(8):2650-8
31. Rizzo G, Passeri D, de Franco F, et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual Farnesoid X Receptor and TGR5 agonist. Mol Pharmacol 2010;78(4):617-30
32. de Marino S, Ummarino R, D'Auria MV, et al. 4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity. Steroids 2012;77(5):484-95. Contains exemplary information on qPCR experiments.
33. Di Leva FS, Festa C, D'Amore C, et al. Binding mechanism of the Farnesoid X Receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. design, synthesis, and biological evaluation of novel ligands. J Med Chem 2013;56(11):4701-17
34. de Marino S, Ummarino R, D'Auria MV, et al. Theonellasterols and conicasterols from theonella swinhoei. novel marine natural ligands for human nuclear receptors. J Med Chem 2011;54(8):3065-75
35. Grienke U, Mihály-Bison J, Schuster D, et al. Pharmacophore-based discovery of FXR-agonists. Part II: Identification of bioactive triterpenes from Ganoderma lucidum. Bioorgan Med Chem 2011;19(22):6779-91
36. Iguchi Y, Kihira K, Nishimaki-Mogami T, Une M. Structure-activity relationship of bile alcohols as human farnesoid X receptor agonist. Steroids 2010;75(1):95-100
37. Hohng S, Lee S, Lee J, Jo MH. Maximizing information content of single-molecule FRET experiments: Multi-color FRET and FRET combined with force or torque. Chem Soc Rev 2014; Epub ahead of print
38. Li G, Lin W, Araya JJ, et al. A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor. Toxicol Appl Pharmacol 2012;258(2):268-74
39. Akwabi-Ameyaw A, Bass JY, Caldwell RD, et al. Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. Bioorgan Med Chem Lett 2008;18(15):4339-43
40. Akwabi-Ameyaw A, Bass JY, Caldwell RD, et al. FXR agonist activity of conformationally constrained analogs of GW 4064. Bioorgan Med Chem Lett 2009;19(16):4733-9
41. Bass JY, Caldwell RD, Caravella JA, et al. Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064. Bioorgan Med Chem Lett 2009;19(11):2969-73
42. Bass JY, Caravella JA, Chen L, et al. Conformationally constrained farnesoid X receptor (FXR) agonists: Heteroaryl replacements of the naphthalene. Bioorgan Med Chem Lett 2011;21(4):1206-13
43. Abel U, Schluter T, Schulz A, et al. Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. Bioorgan Med Chem Lett 2010;20(16):4911-17
44. Urizar NL, A. natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002;296(5573):1703-6
45. Huang H, Yu Y, Gao Z. et al. Discovery and optimization of 1,3,4-trisubstitutedpyrazolone derivatives as novel, potent, and nonsteroidal Farnesoid X Receptor (FXR) selective antagonists. J Med Chem 2012;55(16):7037-53
46. Marinozzi M, Carotti A, Sardella R, et al. Asymmetric synthesis of the four diastereoisomers of a novel non-steroidal farnesoid X receptor (FXR) agonist: Role of the chirality on the biological activity. Bioorgan Med Chem 2013;21(13):3780-9
47. Patching SG. Surface plasmon resonance spectroscopy for characterisation of membrane protein-ligand interactions and its potential for drug discovery. Biochim Biophys Acta 2013; doi: 10.1016/j.bbamem.2013.04.028; Epub ahead of print
48. Choi H, Hwang H, Chin J, et al. Tuberatolides, potent FXR antagonists from the korean marine tunicate botryllus tuberatus. J Nat Prod 2011;74(1):90-4. Describes SPR experiments with FXR.
49. Richter HG, Benson GM, Blum D, et al. Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes. Bioorgan Med Chem Lett 2011;21(1):191-4
50. Richter HG, Benson G, Bleicher K, et al. Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties. Bioorgan Med Chem Lett 2011;21(4):1134-40
51. Nichols JS, Parks DJ, Consler TG, Blanchard SG. Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain. Anal Biochem 1998;257(2):112-19
52. Han K, Kim JH, Kim K, et al. Identification of farnesoid X receptor modulators by a fluorescence polarization-based interaction assay. Anal Biochem 2010;398(2):185-90. Describes a fluorescence polarizationbased FXR binding assay.
53. Yu DD, Lin W, Chen T, Forman BM. Development of time resolved fluorescence resonance energy transferbased assay for FXR antagonist discovery. Bioorgan Med Chem 2013;21(14):4266-78. Development of a FRET-based binding assay with a labeled FXR ligand.
54. Kemper JK, Xiao Z, Ponugoti B, et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab 2009;10(5):392-404
55. Kemper JK. Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications. Biochim Biophys Acta BBAMol Basis Dis 2011;1812(8):842-50. Reviews post-translational modifications of FXR.
56. Gineste R, Sirvent A, Paumelle R, et al. Phosphorylation of farnesoid X receptor by protein kinase c promotes its transcriptional activity. Mol Endocrinol 2008;22(11):2433-47
57. Choi JH, Banks AS, Kamenecka TM, et al. Antidiabetic actions of a nonagonist PPARg ligand blocking Cdk5-mediated phosphorylation. Nature 2011;477(7365):477-81
58. Sepe V, Ummarino R, D'Auria M, et al. Preliminary structure-activity relationship on theonellasterol, a new chemotype of FXR antagonist, from the marine sponge theonella swinhoei. Mar Drugs 2012;10(12):2448-66
59. Lin H. Identification of liver X receptor and farnesoid X receptor dual agonists from Tithonia diversifolia. Med Chem Res 2013;22(7):3270-81
60. Suzuki T, Nishimaki-Mogami T, Kawai H, et al. Screening of novel nuclear receptor agonists by a convenient reporter gene assay system using green fluorescent protein derivatives. Phytomedicine 2006;13(6):401-11
61. Flatt B, Martin R, Wang T, et al. Discovery of XL335 (WAY-362450): A highly potent, selective, and orally active agonist of the Farnesoid X Receptor (FXR). J Med Chem 2009;52(4):904-7
62. Feng S, Yang M, Zhang Z, et al. Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist. Bioorgan Med Chem Lett 2009;19(9):2595-8
63. Soisson SM, Parthasarathy G, Adams AD, et al. Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. Proc Natl Acad Sci USA 2008;105(14):5337-42